A new presentation of the chimeric CYP11B1/CYP11B2 gene with low prevalence of primary aldosteronism and atypical gene segregation pattern

Hypertension

Volumn 59, Issue 1, 2012, Pages 85-91

  Carvajal, Cristian A ^a,d   Campino, Carmen ^a,d   Martinez Aguayo, Alejandro ^b   Tichauer, Juan E ^a   Bancalari, Rodrigo ^b,d   Valdivia, Carolina ^a   Trejo, Pamela ^a   Aglony, Marlene ^b   Baudrand, René ^a   Lagos, Carlos F ^a,c   Mellado, Cecilia ^b   Garcia, Hernán ^b   Fardella, Carlos E ^a,d  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Faculty of Medicine   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d Pontificia Universidad Católica de Chile   (Chile)

Author keywords

chimeric CYP11B1 CYP11B2 gene; familial hyperaldosteronism type I; glucocorticoid remediable aldosteronism

Indexed keywords

18 HYDROXYHYDROCORTISONE; ALDOSTERONE; ALDOSTERONE SYNTHASE; STEROID 11BETA MONOOXYGENASE;

ADOLESCENT; ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL PRESSURE; ARTICLE; CHILD; CLINICAL ARTICLE; EXON; FEMALE; GENE EXPRESSION; GENE SEGREGATION; GENETIC ANALYSIS; HUMAN; HYPERTENSION; INFANT; INHERITANCE; INTRON; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPE; PLASMA RENIN ACTIVITY; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SCHOOL CHILD; SEQUENCE ANALYSIS;

ADOLESCENT; ADULT; ALDOSTERONE; ALDOSTERONE SYNTHASE; CHILE; CHROMOSOME BREAKPOINTS; CHROMOSOME SEGREGATION; FAMILY HEALTH; FEMALE; HUMANS; HYPERALDOSTERONISM; MALE; MUTANT CHIMERIC PROTEINS; PEDIGREE; PREVALENCE; STEROID 11-BETA-HYDROXYLASE;

EID: 83655184721     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.180513     Document Type: Article

References (42)

1. Halperin F, Dluhy RG. Glucocorticoid-remediable aldosteronism. Endocrinol Metab Clin North Am. 2011;40:333-341, viii.
2. Kawamoto T, Mitsuuchi Y, Toda K, Miyahara K, Yokoyama Y, Nakao K, Hosoda K, Yamamoto Y, Imura H, Shizuta Y. Cloning of cDNA and genomic DNA for human cytochrome P-45011. FEBS Lett. 1990;269:345-349. (Pubitemid 20273823)
3. Ogishima T, Shibata H, Shimada H, Mitani F, Suzuki H, Saruta T, Ishimura Y. Aldosterone synthase cytochrome P-450 expressed in the adrenals of patients with primary aldosteronism. J Biol Chem. 1991;266: 10731-10734. (Pubitemid 21906864)
4. Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, Gill JR Jr, Feld L, Ganguly A, Laidlaw JC, Murnaghan DJ, Kaufman C, Stockigt JR, Ulick S, Lalouel JM. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet. 1992;2:66-74.
5. Dluhy RG, Lifton RP. Glucocorticoid-remediable aldosteronism (GRA): diagnosis, variability of phenotype and regulation of potassium homeostasis. Steroids. 1995;60:48-51.
6. Pizzolo F, Trabetti E, Guarini P, Mulatero P, Ciacciarelli A, Blengio GS, Corrocher R, Olivieri O. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens. 2005;19:325-327. (Pubitemid 40514912)
7. Aglony M, Martinez-Aguayo A, Carvajal CA, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Trejo P, Brinkmann K, Giadrosich V, Mericq V, Rocha A, Avila A, Perez V, Inostroza A, Fardella CE. Frequency of familial hyperaldosteronism type 1 in a hypertensive pediatric population: clinical and biochemical presentation. Hypertension. 2011;57:1117-1121.
8. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000;85:1863-1867. (Pubitemid 32269290)
9. Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella CE. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42:161-165. (Pubitemid 36944590)
10. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004;89:1045-1050. (Pubitemid 38368386)
11. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension. 2000;36:495-500.
12. Matsumura K, Fujii K, Oniki H, Oka M, Iida M. Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens. 2006;19:13-18. (Pubitemid 43217027)
13. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab. 2005;90:5070-5076. (Pubitemid 41262256)
14. Mulatero P, Caserta M, Bertello C, Schiavone D, Verhovez A, Giraudo G, Morello F, Veglio F. Aldosterone as an independent factor in cerebrovascular damage. Clin Exp Hypertens. 2008;30:785-797.
15. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969;44:291-303.
16. National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114:555-576.
17. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252. (Pubitemid 37553153)
18. Martinez-Aguayo A, Aglony M, Campino C, Garcia H, Bancalari R, Bolte L, Avalos C, Loureiro C, Carvajal CA, Avila A, Perez V, Inostroza A, Fardella CE. Aldosterone, plasma renin activity, and aldosterone/renin ratio in a normotensive healthy pediatric population. Hypertension. 2010; 56:391-396.
19. Campino C, Carvajal CA, Cornejo J, San Martin B, Olivieri O, Guidi G, Faccini G, Pasini F, Sateler J, Baudrand R, Mosso L, Owen GI, Kalergis AM, Padilla O, Fardella CE. 11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension. Endocrine. 2010;37:106-114.
20. Fardella CE, Pinto M, Mosso L, Gomez-Sanchez C, Jalil J, Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronism without the chimeric CYP11B1/CYP11B2 gene. J Clin Endocrinol Metab. 2001;86:4805-4807. (Pubitemid 33020523)
21. Lahiri DK, Schnabel B. DNA isolation by a rapid method from human blood samples: effects of MgCl2, EDTA, storage time, and temperature on DNA yield and quality. Biochem Genet. 1993;31:321-328. (Pubitemid 23316953)
22. Carvajal CA, Stehr CB, Gonzalez PA, Riquelme EM, Montero T, Santos MJ, Kalergis AM, Fardella CE. A de novo unequal cross-over mutation between CYP11B1 and CYP11B2 genes causes familial hyperaldosteronism type I. J Endocrinol Invest. 2011;34:140-144.
23. Higgins DG. CLUSTAL V: multiple alignment of DNA and protein sequences. Methods Mol Biol. 1994;25:307-318.
24. Brown LD, Cai TT, DasGupta A, Agresti A, Coull BA, Casella G, Corcoran C, Mehta C, Ghosh M, Santner TJ. Interval estimation for a binomial proportion-Comment-Rejoinder. Stat Sci. 2001;16:101-133.
25. Funder JW. Sex and the single gene-FH-1. J Clin Endocrinol Metab. 2000;85:2158-2159.
26. Fallo F, Pilon C, Williams TA, Sonino N, Morra Di Cella S, Veglio F, De Iasio R, Montanari P, Mulatero P. Coexistence of different phenotypes in a family with glucocorticoid-remediable aldosteronism. J Hum Hypertens. 2004;18:47-51. (Pubitemid 38165521)
27. Mulatero P, di Cella SM, Williams TA, Milan A, Mengozzi G, Chiandussi L, Gomez-Sanchez CE, Veglio F. Glucocorticoid remediable aldosteronism: low morbidity and mortality in a four-generation Italian pedigree. J Clin Endocrinol Metab. 2002;87:3187-3191. (Pubitemid 34816363)
28. Stowasser M, Bachmann AW, Huggard PR, Rossetti TR, Gordon RD. Severity of hypertension in familial hyperaldosteronism type I: relationship to gender and degree of biochemical disturbance. J Clin Endocrinol Metab. 2000;85:2160-2166. (Pubitemid 32269238)
29. Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci USA. 1992;89: 4996-5000.
30. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature. 1992;355:262-265.
31. Millis RM. Epigenetics and hypertension. Curr Hypertens Rep. 2011;13: 21-28.
32. Martinerie L, Pussard E, Foix-L'Helias L, Petit F, Cosson C, Boileau P, Lombes M. Physiological partial aldosterone resistance in human newborns. Pediatr Res. 2009;66:323-328.
33. Sippell WG, Dorr HG, Bidlingmaier F, Knorr D. Plasma levels of aldosterone, corticosterone, 11-deoxycorticosterone, progesterone, 17-hydroxyprogesterone, cortisol, and cortisone during infancy and childhood. Pediatr Res. 1980;14:39-46. (Pubitemid 10209376)
34. Lalli E. Adrenal cortex ontogenesis. Best Pract Res Clin Endocrinol Metab. 2010;24:853-864.
35. Kempna P, Fluck CE. Adrenal gland development and defects. Best Pract Res Clin Endocrinol Metab. 2008;22:77-93. (Pubitemid 351218272)
36. Schollen E, Kjaergaard S, Martinsson T, Vuillaumier-Barrot S, Dunoe M, Keldermans L, Seta N, Matthijs G. Increased recurrence risk in congenital disorders of glycosylation type Ia (CDG-Ia) due to a transmission ratio distortion. J Med Genet. 2004;41:877-880. (Pubitemid 39524317)
37. Ikeuchi T, Igarashi S, Takiyama Y, Onodera O, Oyake M, Takano H, Koide R, Tanaka H, Tsuji S. Non-mendelian transmission in dentatorubral-pallidoluysian atrophy and Machado-Joseph disease: the mutant allele is preferentially transmitted in male meiosis. Am J Hum Genet. 1996;58:730-733. (Pubitemid 26086662)
38. Pardo-Manuel de Villena F, Sapienza C. Transmission ratio distortion in offspring of heterozygous female carriers of Robertsonian translocations. Hum Genet. 2001;108:31-36. (Pubitemid 32140539)
39. Pardo-Manuel de Villena F, Sapienza C. Nonrandom segregation during meiosis: the unfairness of females. Mamm Genome. 2001;12:331-339. (Pubitemid 32430052)
40. Aglony M, Acevedo M, Ambrosio G. Hypertension in adolescents. Expert Rev Cardiovasc Ther. 2009;7:1595-1603.
41. Mulatero P, Williams TA, Monticone S, Veglio F. Is familial hyperaldosteronism underdiagnosed in hypertensive children? Hypertension. 2011; 57:1053-1055.
42. Meyer AA, Kundt G, Steiner M, Schuff-Werner P, Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics. 2006;117:1560-1567. (Pubitemid 46071382)